Eyenovia, Inc. (NASDAQ:EYEN) Short Interest Update

Eyenovia, Inc. (NASDAQ:EYEN) saw a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 55,900 shares, a decrease of 96.7% from the January 15th total of 1,690,000 shares. Based on an average daily volume of 350,100 shares, the days-to-cover ratio is currently 0.2 days. Currently, 2.7% of the company’s shares are short sold.

Wall Street Analyst Weigh In

EYEN has been the subject of a number of analyst reports. HC Wainwright reissued a “neutral” rating and set a $2.00 target price on shares of Eyenovia in a research note on Thursday, February 6th. William Blair reissued a “market perform” rating on shares of Eyenovia in a research report on Friday, November 15th. Brookline Capital Management reissued a “hold” rating on shares of Eyenovia in a research note on Friday, November 15th. Finally, LADENBURG THALM/SH SH reaffirmed a “neutral” rating on shares of Eyenovia in a research note on Monday, November 18th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in EYEN. Geode Capital Management LLC increased its holdings in shares of Eyenovia by 36.6% during the third quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock valued at $288,000 after acquiring an additional 149,471 shares in the last quarter. Financial Management Network Inc. bought a new stake in Eyenovia during the 3rd quarter valued at $39,000. Finally, Nations Financial Group Inc. IA ADV lifted its stake in shares of Eyenovia by 78.6% in the third quarter. Nations Financial Group Inc. IA ADV now owns 90,900 shares of the company’s stock valued at $47,000 after buying an additional 40,000 shares in the last quarter. Institutional investors own 25.84% of the company’s stock.

Eyenovia Stock Up 2.8 %

Shares of NASDAQ EYEN opened at $1.85 on Thursday. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.58. The firm has a market cap of $2.57 million, a PE ratio of -0.03 and a beta of 1.24. The company’s fifty day simple moving average is $6.21 and its 200 day simple moving average is $29.74. Eyenovia has a 12-month low of $1.73 and a 12-month high of $205.60.

Eyenovia (NASDAQ:EYEN) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($8.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($10.40) by $1.60. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%. During the same quarter in the previous year, the firm posted ($14.40) EPS. As a group, sell-side analysts forecast that Eyenovia will post -41.6 earnings per share for the current fiscal year.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.